Please assess the completion status of the following clinical trial:

Trial Title: Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, 25 years of age or older~* Diagnosis of any depressive disorder as per DSM IV criteria (except bipolar depression and major depressive disorder with psychotic features). Note: Both patients who are or are not being treated with bupropion or other antidepressants are permitted into the study.~* Patients must have complained of suffering from adverse events and/or lack of effect when switched from Wellbutrin XL® 300 mg to Budeprion XL™ 300 mg.~* BMI (kg/m2) Greater than or equal to 19 and less than or equal to 34.~* No clinically significant abnormal laboratory values~* No clinically significant findings in a 12-lead electrocardiogram (ECG)~* No clinically significant findings in vital signs measurements.~* Be informed of the nature of the study and give written consent prior to receiving any study procedure.~Exclusion Criteria~* Carcinoma within the last 5 years. Note: Patients with basal or squamous cell carcinoma may be permitted into the study on a case by case basis.~* A history of epilepsy or risk for seizures.~* A previous or current diagnosis of bipolar depression.~* A current diagnosis of major depressive episode with psychotic features. Note: Subjects with previous diagnosis of major depressive episode with psychotic features may be included at the investigator's discretion.~* A previous or current diagnosis of an eating disorder (e.g. bulimia, anorexia nervosa).~* A lifetime history of schizophrenia or schizo-affective disorder.~* Significant disease(s) or clinically significant finding(s) in a physical examination determined by an investigator to pose a health concern to the patient while on study.~* Presence of clinically significant gastrointestinal disease and/or surgery (e.g. gastric bypass surgery) or history of malabsorption within the last year.~* Known history or presence of an allergic sensitivity to bupropion and/or any other drug substances with similar activity.~* Expected changes in use of permitted concomitant medication that will be continued throughout the study.~* Undergoing abrupt discontinuation of sedatives (including benzodiazepines).~* Use of monoamine oxidase inhibitors (MAOI) within 2 weeks prior to study admission.~* Taking medications that interact with CYP2B6 within 30 days prior to Day 1 dosing.~* Taking levodopa, amantadine, drugs that lower seizure threshold (e.g. theophylline, systemic steroids, antipsychotics), and/or on nicotine replacement therapy.~* History of alcohol or drug-dependence by DSM IV criteria within 6 months prior to study admission.~* Positive test results for:~  * HIV~ * Hepatitis B surface antigen or Hepatitis C antibody~ * Urine drugs of abuse (i.e. marijuana, amphetamines, barbiturates, cocaine, opiates, methadone, and phencyclidine) Note: any positive test result(s) for benzodiazepine(s) must be assessed by the investigator to determine whether the patient should be excluded from this study.~ * Serum hCG consistent with pregnancy (females only).~* On a special diet within 30 days prior to study admission (e.g. liquid, protein, raw food diet).~* Difficulty fasting or consuming standard meals.~* Participated in another clinical trial or received an investigational product within 45 days prior to Day 1 drug administration.~* Donation or loss of whole blood:~  * Less than or equal to 499 mL within 30 days prior to dosing~ * Greater than or equal to 500 mL within 56 days prior to dosing Note: blood taken for routine medical evaluations totaling less than 50 mL will be permitted.~* Females who have discontinued the use of:~  * implanted, intrauterine, or injected hormonal contraceptives within 6 months prior to Day 1 drug administration, OR~ * oral, intravaginal, or patch hormonal contraceptives within 1 month prior to Day 1 drug administration~* Females who started taking:~  * implanted or intrauterine hormonal contraceptives less than 6 months prior to Day 1 drug administration, OR~ * oral, intravaginal, patch, or injected hormonal contraceptives less than 3 months prior to Day 1 drug administration.~* Females who are pregnant, lactating, or likely to become pregnant during the study.~* Have had a newly applied tattoo or body piercing within 30 days prior to study admission.~* Does not tolerate venipuncture.~* Unable or unwilling to provide informed consent.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Budeprion XL™ (Type: EXPERIMENTAL): Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
- Wellbutrin XL® (Type: ACTIVE_COMPARATOR): Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).